May 7, 2024 Columns by Ahna Crum Recent vision problems with MS remind me to focus on my progress Is there something you now have that you once hoped and prayed for? I’ve been struggling with the demands of a new job for the past few weeks. As a virtual dietitian, I heavily rely on computers to meet with clients and do other necessary work. But staring at a…
May 7, 2024 News by Margarida Maia, PhD Wayne State professor wins grant to study oligodendrocytes in MS Alexander Gow, PhD, a professor at Wayne State University School of Medicine in Detroit, has been awarded a grant to study how stressed oligodendrocytes, the cells that produce myelin in the brain and spinal cord, could be at the origin of multiple sclerosis (MS). The three-year, $644,827 grant from…
May 6, 2024 News by Marisa Wexler, MS Nearly $650k awarded to advance potential remyelination drug IFB-048 The National Multiple Sclerosis Society has awarded Inflectis BioScience a grant valued at $649,601 to advance the preclinical development of IFB-048, the company’s experimental treatment to promote myelin repair in multiple sclerosis (MS). “This grant along with the support from the Society are a testimony…
May 3, 2024 News by Steve Bryson, PhD Charles River to help FibroBiologics produce 3D cell-based therapies Charles River Laboratories has joined up with FibroBiologics to manufacture the company’s spheroids for clinical trials in multiple sclerosis (MS) and several other conditions. The spheroids are groups of fibroblast cells arranged in a three-dimensional (3D) structure that more closely resemble how cells organize in living tissues.